Journal: Bone

Article Title: Abaloparatide promotes bone repair of vertebral defects in ovariectomized rats by increasing bone formation.

doi: 10.1016/j.bone.2024.117056

Figure Lengend Snippet: Fig. 3. ABL increases bone formation without excessive enhancement of bone resorption at the vertebral defect site. (A) Representative images of Hematoxylin- Eosin–stained defected vertebrae after administration. Upper half; overall view, scale bar = 500 μm. Lower half; magnified view, scale bar = 50 μm. (B and C) Representative images of defected vertebrae with immunostaining of ALPase, PHOSPHO1, CatK, and ALPase/PCNA after (B) vehicle or (C) ABL administration. Arrows indicate ALPase/PCNA double-positive preosteoblasts. Scale bar = 50 μm. (D and E) Time-course changes in (D) ALP+Ar/T.Ar and (E) PHOSPHO1+Ar/T.Ar at the vertebral defect site (n = 6 at all timepoints). (F) Time-course changes in N.Oc/BS at the vertebral defect site (n = 6 except for OVX Vehicle With Defect at Week 2 [n = 5]). *P < 0.05, OVX ABL With Defect vs. OVX Vehicle With Defect, †P < 0.05, OVX Vehicle With Defect vs. OVX Vehicle, Tukey’s test.

Article Snippet: Sections were then incubated for 2–3 h at room temperature with rabbit polyclonal antisera against ALPase diluted 1:200 in 1 % BSA-PBS [22], rabbit polyclonal anti-PHOSPHO1 antibody (No. Q8TCT1, Cusabio Technology LLC, Houston, TX, USA) diluted 1:200, and mouse monoclonal anti-CatK antibody (No. F-95, Daiichi Fine Chemical Co., Ltd., Takaoka, Japan) diluted 1:100, followed by incubation with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (No. ab6112, Abcam plc., Cambridge, Cambridgeshire, UK) diluted 1:100 in 1 % BSA-PBS or HRP-conjugated anti-mouse IgG (No. 61-6520, Chemicon International Inc., Temecula, CA, USA) diluted 1:100.

Techniques: Staining, Immunostaining